AYTU BIOPHARMA

Company snapshot

Aytu BioPharma (NASDAQ: AYTU) is a dynamic & growing specialty biopharmaceutical company focused on advancing innovative medicines for complex central nervous system (CNS) diseases to improve the quality of life for patients.

• 2 approved product(s) across US/EU regulatory metadata.
• 3 active pipeline program(s) linked via ClinicalTrials.gov.
• 4 US patent(s) indexed to this assignee profile.

Public regulatory, clinical, patent, and corporate records for AYTU BIOPHARMA. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for AYTU BIOPHARMA.

1. Jun 5, 2026 Clinical update

   Antioxidant — Unknown

2. May 23, 2026 Clinical update

   Enzastaurin — Phase 3

3. May 23, 2026 Clinical update

   ADZENYS XR-ODT — Approved

4. Dec 27, 2022 Patent grant

   Oral compositions for bladder regulation and uses thereof

5. Jan 22, 2019 Patent grant

   Methods and systems for measuring and using the oxidation-reduction potential of a biological sample

View all clinical trial activity →

• What is AYTU BIOPHARMA?

  Aytu BioPharma is a biotech organization headquartered in Denver, USA. It trades on NYSE under ticker AYTU. Primary therapeutic focus areas include Attention Deficit Hyperactivity Disorder, Vascular Ehlers-Danlos Syndrome. NovaPharmaNews links 3 clinical program(s), 2 drug profil

• Is AYTU BIOPHARMA publicly traded?

  Yes. AYTU BIOPHARMA is listed with ticker AYTU on NYSE per SEC EDGAR records linked on this profile.

• What drugs does AYTU BIOPHARMA develop or market?

  We link 5 drug profile(s) where AYTU BIOPHARMA is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/aytu-biopharma-inc#company-drugs.

• What are the latest developments for AYTU BIOPHARMA?

  In the last 12 months our linked public records show 3 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does AYTU BIOPHARMA focus on?

  AYTU BIOPHARMA focuses on Attention Deficit Hyperactivity Disorder, Vascular Ehlers-Danlos Syndrome based on our analysis of their pipeline programs and drug development activities.